HDP-201 / Heidelberg Pharma - LARVOL DELTA

HDP-201 - a novel multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) for treatment of gastrointestinal malignancies (AACR 2025) - "Targeted delivery of topoisomerase 1 inhibitor to GCC-positive cells was achieved using HDP-201 comprised of an anti-GCC antibody conjugated to a multimeric linker-exatecan. HDP-201 showed target-specific potency, strong anti-tumor efficacy, and high tolerability in preclinical models. The use of HDP-201 in the therapy of GCC-positive gastrointestinal malignancies represents a promising approach in cancer treatment."

Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • GUCY2C